Philippe GUÉDAT

Dr Philippe Guédat has over 20 years of experience in drug discovery in the industry. Philippe held positions of responsibility in the “business units”. He was the Director of Chemistry at Hybrigenics and the head of the drug discovery department at Vivalis (now Valneva). His expertise ranges from the discovery of chemical molecules with the implementation of high-throughput screening platforms to clinical development of drug candidates. Philippe has a Master’s degree in medicinal chemistry and pharmacology, a Master’s degree of supramolecular organic chemistry and a PhD in medicinal chemistry and pharmacology from the University Louis Pasteur (Strasbourg). Philippe worked at the University of Cambridge (UK), SmithKline Beecham (UK), Merck-Serono, Hybrigenics and Vivalis (now Valneva). In 2013, he founded InFlectis BioScience where is acting as Chairman and Chief Executive Officer since inception.

Jérôme GUERET

Jérôme Guéret has a deep experience in venture capital industry and financing. Since 2013, Jérôme is partner at GO Capital, one of the leading high tech venture capital in France. Before joining GO Capital, Jérôme was CEO of a high tech electronic company sold to EDF-EN Group in 2008 and was former television VP marketing at Orange Group in 2003. He managed projects and drove strategic execution on new business lines and emerging markets, specifically in telecom and energy sectors. Jerome has a degree from Kedge Business School and an Executive MBA from ESCP Europe.

Taro INABA

Taro Inaba is co-Founder and Managing Partner of Remiges Ventures. He has over 27 years of business development and venture investment experience. Currently he hold positions as a board member at Inflectis Bioscience, Omeicos Ophthalmics, Mitoconix Bio, Digestome Therapeutics and Aqross Therapeutics. Prior to establishing Remiges in 2014, he spent 23 years at Mitsui & Co where he spent the last 13 years being engaged in investment activities including a position as President & CEO at Mitsui & Co Venture Partners in Menlo Park from 2008 to 2009. While he was at Mitsui, he held positions as a board member in 11 companies including Actimis Pharmaceuticals, Boston Biomedical and Hutchison Meidppharma. Taro is co-Founder of Koinobori a philanthropic entity focusing on mitochondrial disease. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. He is a CFA charter holder.

Emilie LIDOME

Emilie Lidome has a biological engineering & management of enterprise background, and joined the venture capital field in 2008. Investment Director at CM-CIC Capital Innovation, a subsidiary of the Crédit Mutuel – CIC group’s investment and merchant bank division, she invests in high technology companies. Before joining CM-CIC Capital Innovation, she worked in the biotechnology & pharmaceutical industries. She led fundamental research projects and has carried out missions of departments’ coordination consulting in companies such as Novartis or GSK. Emilie Lidome has a degree in biological engineering from the Université de Technologie de Compiegne and holds a Master’s Degree in Management of Biotechnology Companies from Grenoble Ecole de Management.

Pierre MINIOU

Dr Pierre Miniou has over 15 years of international experience in business development and licensing in the biopharmaceutical industry with the signing of many partnering and license agreements. He has experience of senior management having been the head of the patent department of Pierre Fabre Laboratories, a member of the Executive Committee of Vivalis (now Valneva) and Director of Vivalis Toyama (Japan). Pierre holds a Master’s degree and Engineering degree in Biotechnology from the School of Biotechnology of Strasbourg and a PhD in Molecular and Cellular Biology from the Louis Pasteur University of Strasbourg. He is also graduated of the CEIPI (Centre for International Studies of Industrial Property) in Strasbourg and has a MBA (Audencia, Nantes). He worked as a researcher at Transgene (Strasbourg), the Wistar Institute (Philadelphia, PA), the Necker Hospital (Paris) and the IGBMC (Strasbourg). He then left the laboratory activities to join the law firm Cabinet Regimbeau (Paris) prior to join Pierre Fabre Laboratories. In 2013, he founded InFlectis BioScience.

Chrisptophe PASIK

Christophe Pasik is the co-founder and past CEO of Keocyt SAS a French pharmaceutical company (2006-2017). He is an active Business Angel, co-founder of several healthcare societies and Board Member of several French Biotech and Healthcare companies. From 1990 to 2006, he held various positions in Pharma companies such as Pfizer, Pharmacia, Catalent and Merck Lipha in France and abroad.